Today’s TR pearl is brought to you by Drs. Shearer, Hernandez, Sun and O’Halloran and summer in the Northeast.

The weather is warm and people are flocking to the great outdoors. This means…ticks, as well as the tick borne diseases they may carry. For how to remove a tick, see Dr. Paulis’s excellent clinical pearl here.

This pearl will be a general review on the various types of tick borne illnesses and what kind of work up they require.

 

Disease Organism Vector Endemic US States In NYC?
Lyme disease Borrelia burgdorferi Ixodes scapularis (blacklegged or deer tick) Northeast and mid-Atlantic esp. CT, DE, ME, MD, MA, NH, NJ, NY, PA, RI, VT, VA, & MN, WI Blacklegged tick found in limited numbers, mostly in Staten Island and the northern Bronx
Babesiosis Babesia microti Northeast & MN, WI
Anaplasmosis Anaplasma phagocytophilum Northeast, esp. NY, CT, NJ, RI & MN, WI
Ehrlichiosis Ehrlichia chaffeensis Amblyomma americanum (lone star tick) Southeast and south-central Lone star tick rare in NYC
RMSF Rickettsia rickettsii Dermacentor variabilis (American dog tick) Throughout US, esp. NC, OK, AR, TN, MO Dog tick found in abundance in all 5 boroughs
   

Lyme disease

Localized Stage
The classic rash associated with lyme disease is erythema migrans (EM)—red ring-like or homogenous expanding rash; classic rash not present in all cases.

Patients may also present with flu-like symptoms – malaise, headache, fever, myalgia, arthralgia, lymphadenopathy. During the localized (early) stage of illness, Lyme disease may be diagnosed clinically in patients who present with an EM rash. Serologic tests may be insensitive at this stage. During disseminated disease, however, serologic tests are usually positive.
Disseminated Stage
In the disseminated stage, patients may present with multiple secondary annular rashes, flu-like symptoms, lymphadenopathy, rheumatologic manifestations, transient, migratory arthritis and effusion in one or multiple joints, migratory pain in tendons, bursae, muscle, and bones, or baker’s cyst. If untreated, arthritis may recur in same or different joints. Cardiac manifestations include conduction abnormalities, e.g. atrioventricular node block,  and myocarditis or pericarditis. Neurologic manifestations include Bell’s palsy or other cranial neuropathies, meningitis, motor and sensory radiculoneuropathy, mononeuritis multiplex, subtle cognitive difficulties, encephalitis, encephalomyelitis, subtle encephalopathy, pseudotumor cerebri (all rare) Additional manifestations include conjunctivitis, keratitis, uveitis, mild hepatitis, splenomegaly.

Laboratory findings include elevated ESR, mildly elevated LFTs, microscopic hematuria or proteinuria. Serologic testing confirms the diagnosis but can be negative in the first few weeks of infection. Treatment regimens for Lyme disease include doxycycline 100 mg, BID orally, cefuroxime axetil 500 mg BID orally, amoxicillin 500 mg, TID for 14-21 days.

Babesiosis

Presents with fever, chills, sweats, malaise, fatigue, myalgia, arthralgia, headache, GI symptoms, dark urine. Less common symptoms include cough, sore throat, emotional lability, depression, photophobia, and conjunctival injection. Mild splenomegaly, mild hepatomegaly, or jaundice may occur in some patients. Laboratory findings include decreased hematocrit due to hemolytic anemia, thrombocytopenia, elevated serum creatinine and BUN, mildly elevated LFTs. Diagnosis is confirmed by identification of intraerythrocytic Babesia parasites by lightmicroscopic examination of a peripheral blood smear; positive Babesia (or B. microti) polymerase chain reaction (PCR) analysis; or isolation of Babesia parasites from a whole blood specimen by animal inoculation (in a reference laboratory). For ill patients, babesiosis usually is treated for at least 7–10 days with a combination of two medications—typically, either atovaquone 750mg q12h  PLUS azithromycin 500–1000 mg on the first day and total daily dose in the range of 250–1000 mg on subsequent days; OR clindamycin 300–600 mg IV every 6 hours OR 600 mg orally every 8 hours PLUS quinine 650 mg orally every 6–8 hours(this combination is the standard of care for severely ill patients). Duration of treatment should be 7-10 days.

Anaplasmosis

Presents with fever, shaking, chills, severe headache, malaise, GI symptoms, cough and in rare cases, a rash. It presents similarly to erlichiosis but the two diseases are transmitted by different tick vectors and occur in different geographic areas. Laboratory findings include mild anemia, thrombocytopenia, leukopenia (characterized by relative and absolute lymphopenia and a left shift); mild to moderate elevations in LFTs may occur in some patients. Visualization of morulae in the cytoplasm of granulocytes during examination of blood smears is highly suggestive of a diagnosis. The diagnosis is confirmed by detection of DNA by PCR of whole blood (most sensitive during the first week of illness) or demonstration of a four-fold change in IgG-specific antibody titer by indirect immunofluorescence antibody (IFA) assay in paired serum samples. Treatment is doxycycline 100mg BID. Patients with suspected anaplasmosis infection should be treated with doxycycline for 10-14 days to provide appropriate length of therapy for possible incubating co-infection with Lyme disease.

Erlichiosis

Presents with fever, headache, chills, malaise, muscle pain, gastrointestinal symptoms (nausea, vomiting, diarrhea, anorexia), confusion, conjunctival injection, rash (more commonly reported among children). As noted above, erlichiosis and anaplasmosis can have similar clinical presentations. Laboratory abnormalities are typically observed during the first week of clinical disease: thrombocytopenia, leukopenia (absolute), anemia (generally occurs later in illness than thrombocytopenia or leukopenia ), and mild to moderate elevations in hepatic transaminases.During the acute stage of illness, morulae can be detected in about 20% of patients. E. chaffeensis most commonly infects monocytes, whereas E. ewingii more commonly infects granulocytes. Also similar to anaplasmosis, the diagnosis is confirmed y detection of DNA by PCR of whole blood (most sensitive during the first week of illness) or demonstration of a four-fold change in IgG-specific antibody titer by indirect immunofluorescence antibody (IFA) assay in paired serum samples. Treatment is doxycycline 100mg BID. Patients should be treated for at least 3 days after the fever subsides and until there is evidence of clinical improvement. Minimum course of treatment is 5–7 days.

RMSF
Presents with fever, chills, severe headache, malaise, myalgia, GI symptoms, photophobia, focal neurologic deficits, including cranial or peripheral motor nerve paralysis or sudden transient deafness. RMSF also presents with a very classic maculopapular rash with small, flat, pink, non-itchy spots (macules) which initially appear on the wrists, forearms, and ankles then spread to the trunk and sometimes palms and soles. Rash typically appears 2–5 days after the onset of fever. Red to purple spots (petechiae) are usually not seen until day 6 or later after onset of symptoms. Petechial rash is considered a sign of progression to severe disease. Every attempt should be made to begin treatment before petechiae develop.

Laboratory findings include thrombocytopenia, mildly elevated hepatic transaminase levels, hyponatremia. Diagnosis is made by detection of DNA in a skin biopsy specimen of a rash lesion by polymerase chain reaction (PCR) assay or in an acute phase whole blood specimen, immunohistochemical (IHC) staining of organism from skin or tissue biopsy specimen or demonstration of a four-fold change in IgG-specific antibody titer by indirect immunofluorescence antibody (IFA) assay in paired serum samples. RMSF is also treated with doxycycline, 100mg BID for at least 3 days after the fever subsides and until there is evidence of clinical improvement.

Center for Disease Control and Prevention. Tickborne Diseases of the US: A Reference Manual for Health Care Providers, Fourth Edition (2017)
NYC Department of Health and Mental Hygiene Advisory #14: Tick Borne Disease Advisory. June 26, 2017.